We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Compare PK, PD and Safety of the AD-213-A and AD-2131

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04690868
Recruitment Status : Completed
First Posted : December 31, 2020
Last Update Posted : April 27, 2022
Sponsor:
Information provided by (Responsible Party):
Addpharma Inc.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
A study to compare safety, pharmacokinetics and pharmacodynamics of AD-213-A to AD-2131 in healthy volunteers.

Condition or disease Intervention/treatment Phase
Gastroesophagus Reflux Disease Drug: AD-213-A Drug: AD-2131 Phase 1

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 43 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open Label, Multi Dose, Cross Over Design Clinical Study to Evaluate the Pharmacokinetic Pharmacodynamic Characteristics and Safety of AD-213-A and AD-2131 After Oral Administration in Healthy Adult Subjects
Actual Study Start Date : October 15, 2021
Actual Primary Completion Date : December 11, 2021
Actual Study Completion Date : December 21, 2021

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: ARM 1
Period 1 : Reference Drug(AD-2131) Period 2 : Test Drug(AD-213-A)
 Drug: AD-213-A
1 tablet administered before the breakfast during 5 days

Drug: AD-2131
1 tablet administered before the breakfast during 5 days
Experimental: ARM 2
Period 1 : Test Drug(AD-213-A) Period 2 : Reference Drug(AD-2131)
 Drug: AD-213-A
1 tablet administered before the breakfast during 5 days

Drug: AD-2131
1 tablet administered before the breakfast during 5 days


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. AUCtau [ Time Frame: From Day 1 up to Day 17 ]
    Evaluation PK after multiple dose

  2. Integrated gastric acidity(%Decrease form baseline) [ Time Frame: 4 times from Day -1 to Day 17 ]
    Evaluation PD after multiple dose


Secondary Outcome Measures :
  1. Cmax [ Time Frame: Day 1 ]
    Evaluation PK after single dose

  2. AUClast [ Time Frame: Day 1 ]
    Evaluation PK after single dose

  3. AUCinf [ Time Frame: Day 1 ]
    Evaluation PK after single dose

  4. Tmax [ Time Frame: Day 1 ]
    Evaluation PK after single dose

  5. t1/2 [ Time Frame: Day 1 ]
    Evaluation PK after single dose

  6. CL/F [ Time Frame: Day 1 ]
    Evaluation PK after single dose

  7. Vd/F [ Time Frame: Day 1 ]
    Evaluation PK after single dose

  8. Cmax,ss [ Time Frame: From Day 1 up to Day 17 ]
    Evaluation PK after multiple dose

  9. Cmin,ss [ Time Frame: From Day 1 up to Day 17 ]
    Evaluation PK after multiple dose

  10. AUCinf [ Time Frame: From Day 1 up to Day 17 ]
    Evaluation PK after multiple dose

  11. Tmax,ss [ Time Frame: From Day 1 up to Day 17 ]
    Evaluation PK after multiple dose

  12. t1/2 [ Time Frame: From Day 1 up to Day 17 ]
    Evaluation PK after multiple dose

  13. CLss/F [ Time Frame: From Day 1 up to Day 17 ]
    Evaluation PK after multiple dose

  14. Vdss/F [ Time Frame: From Day 1 up to Day 17 ]
    Evaluation PK after multiple dose

  15. Integrated gastric acidity(Variations form baseline) [ Time Frame: 4 times from Day -1 to Day 17 ]
    Evaluation PD after multiple dose

  16. Percentage of time to maintain gastric pH 4.0 or higher [ Time Frame: 4 times from Day -1 to Day 17 ]
    Evaluation PD after multiple dose


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy adults over 19 years of age.
  • Weight is more than 50kg and BMI is more than 18.0 kg/m^2 , no more than 27.0 kg/m^2.
  • Subject who has been judged to be eligible for clinical laboratory tests and electrocardiogram tests such as serum tests, hematology tests, blood chemistry tests, and urinary tests conducted within four weeks prior to the administration of clinical trials.
  • Subjects who has heard and fully understood the detailed description of this clinical trial and have willingness to sign of informed consent in writing.

Exclusion Criteria:

  • A subject who has a history that can affect the absorption, distribution, metabolism, or excretion of a drug.
  • As a result of laboratory tests, the following figures: ALT or AST or total bilirubin > 1.5 times upper limit of normal range.
  • As a result of laboratory tests, the following figures: Creatinine clearance < 80mL/min.
  • Subjects who judged ineligible by the investigator.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04690868


Locations
Layout table for location information
Korea, Republic of
Kyungpook National University Hospital
Daegu, Korea, Republic of
Sponsors and Collaborators
Addpharma Inc.
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Addpharma Inc.
ClinicalTrials.gov Identifier: NCT04690868    
Other Study ID Numbers: AD-213PK/PD
First Posted: December 31, 2020    Key Record Dates
Last Update Posted: April 27, 2022
Last Verified: November 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
 Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases